Strides Pharma Science Limited plans to pursue portfolio maximization strategy across the regulated markets to unlock value. It is also exploring to develop a wide range of products across multiple therapeutics segments. Strides is also planning to list its demerged entity–Stelis Biopharma on the exchanges. Recently, the board of directors of Strides approved in principle the demerger of its biotech business under Stelis Biopharma. The company also roped in Aditya Puri to the board of Stelis Biopharma.